Min Yan

11PUBLICATIONS
59CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jun 19, 2025
Distress thermometer and determinants of psychological distress in metastatic breast cancer.

Huihui Sun, Huimin Lv, Limin Niu

|May 09, 2025
Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort.

Xichun Hu, Qingyuan Zhang, Tao Sun

|Apr 22, 2025
Application of Neoadjuvant Docetaxel plus Cisplatin in Early-Stage Triple-Negative Breast Cancer (HELEN-001): Results from a Phase II Trial.

Dechuang Jiao, Jianghua Qiao, Xianfu Sun

|Jan 02, 2025
Intravenous liposomal irinotecan in metastatic triple-negative breast cancer after ≥ 2 prior lines of chemotherapy: a phase Ib study.

Ying Fan, Qingyuan Zhang, Min Yan

|Oct 01, 2024
Sacituzumab govitecan in HR+HER2- metastatic breast cancer: the randomized phase 3 EVER-132-002 trial.

Binghe Xu, Shusen Wang, Min Yan

|Jun 20, 2024
Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2-Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2-Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial.

Herui Yao, Min Yan, Zhongsheng Tong

Pageof 2

Frequent Collaborators

3 joint publications

Zhenzhen Liu

3 joint publications

Xiaojia Wang

3 joint publications

Shusen Wang

3 joint publications

Binghe Xu